Clinical Trial

ORION-10 A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Study Status:

Active, Not recruiting

Contact Information:

(956) 362-2378

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The purpose is to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) inclisiran injection(s) in patients with atherosclerotic cardiovascular disease and elevated LDL – C (Bad Cholesterol)

Information:

Principal Investigator	Mahesh Changlani, MD
Co-PI	John Rodriguez
Sponsor	The Medicines Comapany
Type of Trial	Interventional

Contact Us For More Info Or To Apply

5323 S. McColl Rd., Edinburg, TX 78539

[email protected]

(956) 362-2390

Clinical Trial

ORION-10 A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Study Status:

Contact Information:

Study Purpose:

Information:

Useful Links

For Research Participants

About Us

News & Views